Equity investment follows recent EUR 520 m licensing agreement providing Grand Pharma (GP) access to three of ITM’s targeted radionuclide therapeutic and diagnostic candidates for Greater China
The company is doubling its chemistry research capacity that should commission by Q2'FY22
This investment is being made to set up a high speed 400 vials a minute injectable fill line with isolator technology
Jubilant successfully challenged Bracco's patent infringement claims in an Inter Parties Review (IPR) proceeding before the U.S. Patent Office
Subscribe To Our Newsletter & Stay Updated
